Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection.
Serum and intrahepatic hepatitis C virus (HCV) RNA were measured in 37 HIV-HCV co-infected patients with controlled human immunodeficiency virus (HIV) infection and correlated with clinical, biological, and histological parameters. Thirty-seven interferon-naive patients underwent liver biopsy. HCV-induced activity (A) and fibrosis (F) were evaluated with METAVIR score. The 37 patients included had HIV plasma loads < 10,000 copies/ml, CD4(+) count > 250/microl. All the patients but two were receiving antiretroviral treatment. Liver tissue and sera were used for measurement of HCV RNA by the Cobas Amplicor HCV Monitor. All patients had serum and liver HCV RNA, and both levels were correlated (r = 0.47; P = 0.003). Intrahepatic HCV load did not depend on age, sex, duration of HCV infection, CD4(+), HCV genotype, or fibrosis. AST levels correlated with intrahepatic HCV load (r = 0.52; P = 0.001). Patients with METAVIR A1/A2 had significantly lower levels of liver HCV-RNA than were found in patients with METAVIR A3 (P = 0.026). Highly active antiretroviral therapy (HAART) including protease inhibitors(PI)-treated patients had significantly lower intrahepatic HCV load (P = 0.04). A weak but significant correlation between serum and liver HCV RNA was found. The amount of hepatic HCV RNA was correlated with AST levels, histological activity, but not with HCV genotype or fibrosis. The immune improvement associated with PI regimens could help reduce HCV load, supporting a protective effect of PI-induced immune restoration.
Trimoulet
P
P
Laboratoire de Virologie, Centre Hospitalo-Universitaire, Bordeaux, France. pascale.trimoulet@chu-bordeaux.fr
Neau
D
D
Le Bail
B
B
Rullier
A
A
Winnock
M
M
Galperine
T
T
Legrand
E
E
Schvoerer
E
E
Dupon
M
M
Ragnaud
J M
JM
Bioulac-Sage
P
P
Chêne
G
G
Fleury
H
H
Lafon
M E
ME
D000328:Adult; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1 / Q000502:physiology; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology*; D006526:Hepatitis C / Q000150:complications* / Q000473:pathology / Q000821:virology; D006801:Humans; D008099:Liver / Q000821:virology*; D008297:Male; D012367:RNA, Viral / Q000032:analysis* / Q000097:blood; D019562:Viral Load
D017320:HIV Protease Inhibitors; D012367:RNA, Viral